Approval In Brief
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer's Aromasin for early breast cancer: Pfizer's oncologic Aromasin (exemestane) clears FDA Oct. 5 for adjuvant treatment of early breast cancer in patients crossing over from tamoxifen therapy. Aromasin's additional indication is for "adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer following two to three years of tamoxifen for a completion of five consecutive years of adjuvant hormonal therapy," Pfizer says. The firm's Intergroup Exemestane Study found a 31% reduced risk of recurrence in patients switching to Aromasin versus those remaining on tamoxifen. Aromasin previously was approved for advanced breast cancer in patients whose disease progressed following tamoxifen therapy...
You may also be interested in...
Chiron Fluvirin production
Chiron expects a full production season in 2006-2007 of 40 mil. doses for its influenza vaccine Fluvirin, the firm says Oct. 17. The company reports it has shipped 1.5 mil. doses of this year's formulation so far but that production for the full 2005-2006 season will be lower than previously expected. Chiron says it will not provide revised total production estimates for the current season. FDA released three lots of Fluvirin Sept. 14 (1Pharmaceutical Approvals Monthly October 2005, p. 16). "Despite Chiron's lowered projections announced today, we still anticipate that there will be significantly more vaccine produced than last year," FDA said in a same-day press release...
Elan Prialt Intrathecal Delivery Effectively Limits Use To Experts, FDA Concludes
Intrathecal administration effectively limits use of Elan's Prialt (ziconotide) to specialists, a de facto restriction that tempered FDA concerns about a drug characterized by what one agency official called "profound toxicity" and "meager" efficacy
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011